Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial
The objective of this study is to evaluate the efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with CHD and GID undergoing PCI. We aim to explore an optimized antithrombotic strategy, which achieves the same anti-ischemic effect as standard DAPT without increasing the risk of GIB, for patients with CHD and GID undergoing PCI.Trial registrationThis protocol is registered at the Chinese Clinical Trial Registry under the number ChiCTR2100044319. And this publication is based on version 1.4 of the trial protocol dated Sep 6, 2021. (Source: Trials)
Source: Trials - March 21, 2023 Category: Research Source Type: clinical trials
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
Conditions: Coronary Artery Disease; Platelet Reactivity Interventions: Drug: CYP2C19 genotype guided P2Y12 monotherapy; Drug: Clopidogrel Sponsor: St. Antonius Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 17, 2023 Category: Research Source Type: clinical trials
